

REPORT FROM SCANDINAVIAN PROSTATIC CANCER GROUP (SPCG)

SPCG has worked actively during the last two years. The group has been chaired by Teuvo Tammela and Klaus Brasso has worked as the secretary. The Board consisting of ordinary members (two per country) and affiliated members has had annually at least two meetings. In addition, the investigators of the special studies have had their own meetings focusing on the special questions of that study. SPCG arranged Scandinavian Prostate Cancer Group Trial meeting for all investigators and study nurses in Johannesbergs Slott outside Uppsala in Sep. 30 – Oct. 1, 2010. One uro-oncologist from each Nordic Country has worked as an affiliated member. This has offered oncological expertise and more opportunities to start new kind of studies that require co-work between urologists and oncologists. The uro-oncologists have brought a lot of new ideas and new way of thinking into the group influencing the three newest studies (SPCG -12, SPCG-13 and SPCG-14). Other affiliated members have been the principal investigators of ongoing SPCG trials. See enclosed the list of members.

The SPCG-5 Study (High-elyestradiolhosphate versus total androgen blockade) has been closed and the final evaluation has been published. Evaluation of other results of the study are still in progress, including quality of life, during treatment with parenteral estrogen in prostate cancer patients. Paper on cardiovascular risk factors has been published in Scand J Urol Nephrol in this year.

SPCG-7 Study (Randomised trial of locally advanced prostate cancer. Antiandrogen treatment with or without radiotherapy) was started in 1996 and it recruited 880 patients in two arms. Its main results were reported in Lancet. The analysis showed that addition of radiotherapy gives a clear benefit over pure endocrine therapy in the treatment of local or locally advanced prostate cancer. The follow-up continues and the results are updated in this year. In conjunction with SPCG-7 Study there has also been running a biopsy study, the results of which were published in two papers in this year.

SPCG-11 Study (Effectiveness of Zometa treatment for prevention of bone metastases in high risk prostate cancer patients) started in 2004 as collaboration between SPCG and German Arbeitsgemeinschaft Urologische Onkologie (AUO) and with EAU. EAU coordinates the study and manages the database, while SPCG runs and monitors the Scandinavian part, which can also be analysed and reported separately after common analysis of the whole study. This gives autonomy thought to be important in this kind of collaboration. Main reason for collaboration was the high number (1500) of patients needed to reach the statistical power. Novartis is supporting the study by donating a grant to the SPCG Foundation. In SPCG 224 patients have been included. Their follow-up is still continuing.

SPCG-12 Study (An open randomised phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 and Gleason $\geq 3+4$ margin positive pT2/AdPro) focuses on adjuvant docetaxel treatment in patients undergoing radical prostatectomy but have poor prognostic factors. It is the only SPCG Study in which all the five Nordic Countries are participating. The study is done in close collaboration with uro-oncologists. The study started in 2005 and has reached the goal of 480 randomized patients. The number of randomized patients was increased from the original goal of 400 to reach surely the statistical power needed.

SPCG-13 Study (A Randomized phase III trial of six cycles of docetaxel versus surveillance plus hormonal treatment after radical radiotherapy in patients with intermediate or high-risk prostate

cancer/AdRad) focuses similarly on adjuvant docetaxel treatment in patients treated with radiotherapy but have poor prognostic factors. The uro-oncologists have a leading role in this trial. The study started in 2006. Due to delays in recruitment the statistics have been re-evaluated and the number of the aimed patients has been decreased to 378. At the moment the study is close to reach this goal.

SPCG-14 Study (A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation +/- Docetaxel for Non metastatic Prostate Cancer Patients with a Rising PSA) recruits patients who have prostate cancer without metastases with rising PSA following curative treatment (RP or RT) and PSA > 10 or PSA doubling time < 6 months & PSA>5 and patients planned for antiandrogen treatment (castration) with PSA of 20-100 and PSA doubling time < 6 months or Gleason score ≥ 8 . Antiandrogen treatment only is compared with antiandrogen treatment in combination with docetaxel. The primary endpoint is PSA progression free survival and the secondary endpoints are time to metastatic disease, cancer specific survival, overall survival and quality of life (FACT-P-T). The goal is include 215 patients per arm. The recruitment of patients to this study has been slower than expected. Problems in monitoring can be anticipated, as the patient has run out.

Although SPCG studies last for a very long time most of them are completed and produce data which no other study groups have been able to produce. The long duration causes problems with sponsors which are not so willing to continue their support accordingly. At the moment this is partly true in the studies testing docetaxel. The problems have mostly been succeeded to overcome so far. However, the situation of SPCG 14 does not look so promising. Although the economical situation of SPCG Foundation is not as bad as it was 5 - 6 years ago due to the efforts made by the group the future looks very challenging.

Most of the SPCG studies have been sponsored, at least partly, by drug companies, which seems to be important also in the future because there are no other realistic possibilities to find in the Nordic Countries all the money needed to cover the costs of clinical trials. The co-work with companies, however, necessitates that SPCG has a crucial role in planning protocols and has also an access to the database. On the other hand, the companies are not any more willing and permitted to support the investigator initiated trials as much as previously which, in association with the EU directive, has increased enormously the work load of the principal and coordinating investigators. This has made it more difficult to start and conduct good clinical trials. However, SPCG is most powerful in conducting clinical multi-centre trials and I think this is what the group should also aim do in the future. Basic research can be included in these studies whenever possible. Another option is to develop collaboration with other study groups or the EAU which have more sponsoring from other sources. In this case the SPCG must make sure to have autonomy in order to keep identity of its own. In any case, it looks like SPCG will need this kind of collaboration in the future.

Tampere on August 21, 2011

Teuvo Tammela
Chairman of SPCG

Members of SPCG

- Göran Ahlgren, Ordinary member, Principal investigator SPCG-12, Överläkare M.D., Ph.D. Urologiska kliniken Universitetssjukhuset MAS 205 02 Malmö, Sverige Tel +46 0708-179315
E-mail goran.ahlgren@skane.se
- Anders Angelsen, Affiliated member, SPCG-7 Biopsy Study, SPCG-11, SPCG-12. Senior Consultant/Associate professor MD PhD. Dept of Urology, St. Olavs University Hospital, and Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology. N-7006 Trondheim. Norway Tel.+47 7386 8000 Fax +47 7386 7428
e-mail anders.angelsen@ntnu.no
- Viktor Berge, Affiliated member, SPCG-14, EORTC-Gu Global group contact member, Overlege dr. med. Urologisk sektion, Sentralsykehuset i Akershus, NO 1474 Nordbyhagen, Norge Tel. +47 6792 8800 Fax. +47 6792 9112
e-mail Viktor.Berge@akersykehus.no
- Rene Blom, Affiliated member, uro-onkologist. Överläkare Onkologiska kliniken, Universitetssjukhuset i Lund, SE 221 85 Lund, Sverige Tel +46 4617 7520
e-mail rene.blom@skane.se
- Michael Borre, Ordinary member, overlæge, dr. med., Ph.d. Urologisk afdeling K, Århus Universitets Hospital, Skejby Sygehus, Brendstrupgårdsvej, DK-8200 Århus N, Danmark
Tel. +45 8949 5566 bipper 5909 Fax. +45 8949 6006
e-mail borre@dadlnet.dk
- Klaus Brasso, Secretary, overlæge, Ph.d., Urologisk afdeling D, Rigshospitalet, Blegdamsvej 9, DK 2100 København, Danmark.
Tel. +45 3545 3545 private +45 4587 8187
Fax. +45 3545 2158
e-mail brasso@dadlnet.dk
e-mail klausbrasso@hotmail.com
- Bjørn Brennhovd, Ordinary member, Overlege Kirurgisk avdeling Rikshospitalet - Radiumhospitalet Montebello NO 0310 Oslo, Norge
Tel +47 2293 4000 Fax +47 2293 5944
e-mail: bjorn.brennhovd@radiumhospitalet.no
- Jan-Erik Damber, Affiliated member, SPCG-11, Professor Enheten för Urologi, Universitetssjukhuset Sahlgrenska, SE 413 45 Göteborg, Sverige
Tel. +46 31 342 397 Fax +46 3141 6347
E-mail jan-erik.damber@urology.gu.se

- Per Olov Hedlund, Affiliated member, Chairman SPCG-Stiftelsen, Principal invest. SPCG-5, Docent emeritus, Urologiska kliniken, Karolinska sjukhuset, Stockholm, Sverige.
Private: Skogsstigen 22, SE 131 42 Nacka, Sverige
Tel. +46 8716 7659 Fax. +46 8716 9662
E-mail krea@beta.telenordia.se
- Jonas Hugosson, Affiliated member, Posaproca/SPCG. Docent
Enheten för urologi, Bruna stråket 11, Sahlgrenska, SE 413 45 Göteborg, Sverige Tel +46 31342 3820 Fax +46 3141 5648
e-mail jonas.hugosson@urology.gu.se
- Morten Høyer, Affiliated member, uro-oncologist, Overlæge Ph.D, Onkologisk afdeling D, Århus Kommunehospital, Nørrebrogade 44, DK-8000 Århus, Danmark Tel. +45 8949 2529 Fax. +45 8949 2530
e-Mail hoyer@as.aaa.dk
- Jon Reidar Iversen, Affiliated member, oncologist, Overlæge, Urologienheten, Kreftsenteret, Ullevål University Hospital HF, N-0407 Oslo, Norge
Tel. +47 2302 6600 Fax. +47 2302 6601
e-mail joiv.@uus.no
- Peter Iversen, Affiliated member, Principal investigator SPCG-6, Professor, overlægeUrologisk afdeling D, Rigshospitalet, Blegdamsvej 9, DK 2100 København, Danmark Tel. +45 3545 2314 Fax. +45 3545 2158, e-mail piv@rh.dk
- Jan-Erik Johansson, Affiliated member, Principal investigator SPCG-4, Docent
Urologiska kliniken, Regionssjukhuset, SE 701 85 Örebro, Sverige
Tel. +46 19 602 1977 Fax +46 1918 5190
e-mail erik.johansson@orebroll.se / irene.pettersson@orebroll.se
- Pirkko-Liisa Kellokumpu-Lehtinen, Affiliated member, uro-oncologist, Professor and Chairman of
Department of Oncology, Tampere University Hospital, P. O. Box 2000, FIN-33521 Tel. +358 3 3116 3227 Mobile +358 50 5951103
Fax. +358 3 3116 3009
e-mail Pirkko-Liisa.Kellokumpu-Lehtinen@uta.fi
- Peter Klarskov, Affiliated member, Overlæge, dr. med., Department of Urology, Herlev Hospital, DK 2730 Herlev Danmark
Tel. +45 4488 4000 ext 82502
Fax +45 4488 4736, e-mail petkla01@heh.regionh.dk
Private tel. +45 4399 3295, e-mail pekl@dadlnet.dk.
- Per Lundmo, Affiliated member, Board member SPCG-Foundation, Overlege, Urologisk seksjon, St Olavs Hospital HF, NO 7006 Trondheim, Norge
Tel. +47 7386 8000 Fax. +47 7386 9495
e-mail per.i.lundmo@medisin.ntnu.no

- Mika Matikainen, Ordinary member,
Department of Urology, Tampere University Hospital, P. O. Box 2000,
FIN-33521 Tampere, Finland Tel. +358 3 3116 5017 Fax +358 3 3116
4371
e-mail mika.matikainen@uta.fi
- Knud Pedersen, Affiliated member, Danish coordinator SPCG-9. Overlæge dr. med.
Urologisk afdeling K, Skejby Sygehus, Brendstrupgårdsvej, 8200 Århus
N, Danmark Tel. +45 8949 5900 Fax. +45 8949 6006
e-mail kvp@sks.aaa.dk
- Finn Rasmussen, Affiliated member, Secretary SPCG-Stiftelsen,
fira@webspeed.dk
Private Ellemosevej 79, DK 2900 Hellerup. Tel. +45 3965 7551
- Johan Stranne Affiliated member. Dept. Of Urology, Sahlgrenska University Hospital.
S-41315
e-mail johan.stranne@vgregion.se
- Niels Svolgaard Ordinary member, Overlæge Urinvejskirurgisk afdeling, Odense
Universitetshospital. Tlf. 65413868
e-mail niels.svolgaard@ouh.regionsyddanmark.dk
- Kimmo Taari, Ordinary member, Chief of Department, Docent, MD, PhD, FEBU
Department of Urology, Helsinki University Central Hospital, P.O. Box
580, FIN-00029 HUS, Helsinki, Finland Tel. mobile +358 50 4270057
Fax +358 9 4716 3392
e-mail kimmo.taari@hus.fi
- Teuvo Tammela, Chairman Ordinary member, Professor and Chief of Urology, Chairman
of Department of Surgery, Department of Urology, Tampere University
Hospital, P. O. Box 2000. FIN-33521 Tampere, Finland
Tel. +358 33116 4621 Fax +358 33116 4371 Mobile +358 40 557 4492
e-mail teuvo.tammela@uta.fi
- Anders Widmark, Affiliated member, Principal investigator SPCG-7, Professor, PhD.
Onkologiska kliniken, Norrlands Universitetssjukhus, SE 901 85 Umeå,
Sverige
Tel. +46 90 785 2857 Mobile +46 70 5844330 Fax +46 90 774 646
e-mail anders.widmark@onkologi.umu.se
- Terje Wold, Ordinary member, Sentralsykehuset in Kristiansand
e-mail terje.wold@sshf.no